Cardiac xenotransplantation: recent preclinical progress with 3-month median survival.

Abstract

OBJECTIVES Transplantation is limited by a lack of human organ donors. Organs derived from animals, most likely the pig, represent a potential solution to this problem. For the heart, 90-day median graft survival of life-supporting pig hearts transplanted to nonhuman primates has been considered a reasonable standard for entry into the clinical arena. Overcoming the immune barrier to successful cardiac xenotransplantation is most appropriately first explored with the non-life-supporting heterotopic model. METHODS We performed a series of 7 heterotopic heart transplantations from CD46 transgenic pigs to baboons using a combination of therapeutic agents largely targeted at controlling the synthesis of anti-pig antibodies. Rituximab (anti-CD20) and Thymoglobulin (rabbit antithymocyte globulin [ATG]; SangStat Medical Corp, Fremont, Calif) were used as induction therapy. Baseline immunosuppression consisted of splenectomy, tacrolimus, sirolimus, steroids, and TPC (an anti-Gal antibody therapeutic). Rejection events were not treated. RESULTS By using Kaplan-Meier analysis, median graft survival was 96 days (range, 15-137 days; 95% confidence interval, 38-99 days). Only 2 grafts were lost as a result of rejection, as defined by cessation of graft palpation. There was no evidence of a consumptive coagulopathy, infectious complications were treatable, and no posttransplantation lymphoproliferative disorders occurred. No cellular infiltration was observed. CONCLUSIONS This study reports the longest median survival to date (96 days) of pig hearts transplanted heterotopically into baboons. Duplication of these results in the orthotopic life-supporting position could bring cardiac xenotransplantation to the threshold of clinical application.

5 Figures and Tables

05010020072008200920102011201220132014201520162017
Citations per Year

271 Citations

Semantic Scholar estimates that this publication has 271 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Mcgregor2005CardiacXR, title={Cardiac xenotransplantation: recent preclinical progress with 3-month median survival.}, author={Christopher Mcgregor and William R. Davies and Keiji Oi and Sumeet S Teotia and Johannes M Schirmer and Jack M Risdahl and Henry Dale Tazelaar and Walter Karl Kremers and Randall C . Walker and Guerard W. Byrne and John S. Logan}, journal={The Journal of thoracic and cardiovascular surgery}, year={2005}, volume={130 3}, pages={844-51} }